OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On February 27, 2018, Oxford Immunotec Global PLC (the “Registrant”) issued a press release announcing its financial results for the fourth quarter of 2017 and fiscal year 2017.The full text of the press release and the related attachment are furnished as Exhibit 99.1 hereto and incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibits

Oxford Immunotec Global PLC Exhibit
EX-99.1 2 ex_106167.htm EXHIBIT 99.1 ex_106167.htm Exhibit 99.1     Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results     ● 2017 marks the 13th consecutive year of at least 20% year-over-year constant currency revenue growth   ● >25% pro forma organic growth for the year in tick-borne disease and other revenue   ● Balance sheet strengthened by December patent infringement settlement,…
To view the full exhibit click here

About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.